title: [Methadone and sleep apnea syndrome].
abstract: BACKGROUND
  Sleep apnea syndrome occurs when, during sleep, breathing stops for 10 seconds or longer, with an index of 5 times or more an hour. It is clinically characterized by loud snoring at night, continuous or interrupted by pauses followed by loud breathing. Sleep is fitful, broken by arousals, and yields little rest. There is daytime excessive sleepiness with repeated involuntary falling asleep, often unknown by the subject.
  
  
  METHODS
  In this article, we describe an observation of central sleep apnea syndrome in a female patient receiving an opiate replacement therapy.
  
  
  METHODS
  An analysis of the before and after methadone withdrawal polysomnograhic tracing was done for this patient.
  
  
  RESULTS
  This diagnosis etiology and physiopathology are critically approached. Clinicians should be careful in treating induced sleep disorders in such patients.
  
  
  CONCLUSIONS
  Prescribing benzodiazepines during an opiate withdrawal of the methadone type is not recommended when central apnea occurs.
authors.affiliation: Centre Hospitalier Sainte Marie, Réseau ERAHSM, Privas, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Durst
authors.forename: Jérôme
authors.initials: J
authors.lastname: Palazzolo
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Peyrelong
authors.forename: Michel
authors.initials: M
authors.lastname: Berger
authors.forename: Michel
authors.initials: M
authors.lastname: Chalabreysse
authors.forename: Michel
authors.initials: M
authors.lastname: Billiard
authors.forename: André
authors.initials: A
authors.lastname: Vialle
mesh_terms: D000328:Adult; D001921:Brain / Q000187:drug effects; D003000:Clonidine / Q000009:adverse effects / Q000627:therapeutic use; D019970:Cocaine-Related Disorders / Q000534:rehabilitation; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006556:Heroin Dependence / Q000534:rehabilitation; D006801:Humans; D006919:Hydroxyzine / Q000009:adverse effects / Q000627:therapeutic use; D008691:Methadone / Q000009:adverse effects* / Q000627:therapeutic use; D008728:Methotrimeprazine / Q000009:adverse effects / Q000627:therapeutic use; D009293:Opioid-Related Disorders / Q000534:rehabilitation*; D017374:Paroxetine / Q000009:adverse effects / Q000627:therapeutic use; D017286:Polysomnography / Q000187:drug effects; D020182:Sleep Apnea, Central / Q000139:chemically induced*; D012894:Sleep Stages / Q000187:drug effects; D013375:Substance Withdrawal Syndrome / Q000209:etiology*; D014291:Trimeprazine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D006919:Hydroxyzine; D017374:Paroxetine; D014291:Trimeprazine; D008728:Methotrimeprazine; D003000:Clonidine; D008691:Methadone